Investigational Drug Information for Mizoribine
✉ Email this page to a colleague
What is the drug development status for Mizoribine?
Mizoribine is an investigational drug.
There have been 6 clinical trials for Mizoribine.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2022.
The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Lupus Nephritis. The leading clinical trial sponsors are Asahi Kasei Pharma Corporation, Lee's Pharmaceutical Limited, and Chong Kun Dang Pharmaceutical.
There are six hundred and eighteen US patents protecting this investigational drug and zero international patents.
Summary for Mizoribine
| US Patents | 618 |
| International Patents | 12,852 |
| US Patent Applications | 6,441 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 1,199 |
| Clinical Trial Progress | Phase 3 (2022-05-01) |
| Vendors | 58 |
Recent Clinical Trials for Mizoribine
| Title | Sponsor | Phase |
|---|---|---|
| Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients | Lee's Pharmaceutical Limited | Phase 4 |
| An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients | Lee's Pharmaceutical Limited | Phase 4 |
| A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) | Regeneron Pharmaceuticals | Phase 3 |
Clinical Trial Summary for Mizoribine
Top disease conditions for Mizoribine
Top clinical trial sponsors for Mizoribine
US Patents for Mizoribine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Mizoribine | ⤷ Sign Up | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | Dana-Farber Cancer Institute, Inc. (Boston, MA) | ⤷ Sign Up |
| Mizoribine | ⤷ Sign Up | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | ⤷ Sign Up |
| Mizoribine | ⤷ Sign Up | Compounds useful for the treatment of metabolic disorders and synthesis of the same | North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC) | ⤷ Sign Up |
| Mizoribine | ⤷ Sign Up | Cellulose micropowder | ASAHI KASEI KABUSHIKI KAISHA (Tokyo, JP) | ⤷ Sign Up |
| Mizoribine | ⤷ Sign Up | Cured gel and method of making | ATRIUM MEDICAL CORPORATION (Merrimack, NH) | ⤷ Sign Up |
| Mizoribine | ⤷ Sign Up | .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof | Quadriga Biosciences, Inc. (Los Altos, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Mizoribine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Mizoribine | Australia | AU2011210567 | 2030-01-29 | ⤷ Sign Up |
| Mizoribine | Canada | CA2787784 | 2030-01-29 | ⤷ Sign Up |
| Mizoribine | European Patent Office | EP2528893 | 2030-01-29 | ⤷ Sign Up |
| Mizoribine | European Patent Office | EP3138838 | 2030-01-29 | ⤷ Sign Up |
| Mizoribine | Japan | JP2013518816 | 2030-01-29 | ⤷ Sign Up |
| Mizoribine | Japan | JP2016183175 | 2030-01-29 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
